Abbvie Inc.

Blas Coll Crespo

James C Stolzenbach

Dennis Andress

John J Brennan

The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol.

Growing community of inventors

Highland Park, IL, United States of America

Blas Coll Crespo